BiotechTube

REC-4881 + Placebo

Phase 1/2Recruiting
0 views this week 0 watching💤 Quiet
Interest: 33/100
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Familial Adenomatous Polyposis

Conditions

Familial Adenomatous Polyposis

Trial Timeline

Jul 10, 2023 → Jul 1, 2026

NCT ID
NCT05552755

About REC-4881 + Placebo

REC-4881 + Placebo is a phase 1/2 stage product being developed by Recursion Pharmaceuticals for Familial Adenomatous Polyposis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05552755. Target conditions include Familial Adenomatous Polyposis.

What happened to similar drugs?

1 of 20 similar drugs in Familial Adenomatous Polyposis were approved

Approved (1) Terminated (3) Active (17)
🔄SHR-1209 ;placebo + SHR-1209 ;placebo + SHR-1209 ;placeboJiangsu Hengrui MedicinePhase 3
🔄Rosuvastatin 20mg + PlaceboAstraZenecaPhase 3
🔄rosuvastatin calcium + rosuvastatin calcium + rosuvastatin calciumAstraZenecaPhase 3
🔄Rosuvastatin + PlaceboAstraZenecaPhase 3
🔄Rosuvastatin 20mgAstraZenecaPhase 3
🔄AZD0780 + PlaceboAstraZenecaPhase 3
🔄Anacetrapib + Placebo for anacetrapibMerckPhase 3

Hype Score Breakdown

Clinical
9
Activity
15
Company
9
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05552755Phase 1/2Recruiting

Competing Products

20 competing products in Familial Adenomatous Polyposis

See all competitors
ProductCompanyStageHype Score
Bromocriptine Mesilate + PlacebosTowa PharmaceuticalPhase 1/2
32
SHR-1209Jiangsu Hengrui MedicinePhase 2
31
SHR-1209 ;placebo + SHR-1209 ;placebo + SHR-1209 ;placeboJiangsu Hengrui MedicinePhase 3
40
Rosuvastatin 20mg + PlaceboAstraZenecaPhase 3
40
rosuvastatin calcium + rosuvastatin calcium + rosuvastatin calciumAstraZenecaPhase 3
40
Rosuvastatin + PlaceboAstraZenecaPhase 3
40
Rosuvastatin 20mgAstraZenecaPhase 3
40
AZD0780 + PlaceboAstraZenecaPhase 3
44
Anacetrapib + Placebo for anacetrapibMerckPhase 3
40
Statins and EzetimibeMerckPre-clinical
22
Comparator: niacin (+) laropiprant (MK0524A) + Comparator: placeboMerckPhase 3
32
MK-0524A + MK-0524AMerckPhase 1
21
Enlicitide Decanoate + PlaceboMerckPhase 2/3
45
Inclisiran + PlaceboNovartisPhase 3
40
DFV890NovartisPhase 2
35
CanakinumabNovartisPhase 2
35
Inclisiran Sodium for injection + Placebo + PlacebosNovartisPhase 3
40
LCQ908 + PlaceboNovartisPhase 3
40
InclisiranNovartisPhase 3
44
Inclisiran + PlaceboNovartisPhase 3
40